Waypoint Wealth Partners Inc. Raises Stock Position in Johnson & Johnson (NYSE:JNJ)

Waypoint Wealth Partners Inc. grew its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 11.8% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 12,093 shares of the company’s stock after purchasing an additional 1,273 shares during the period. Johnson & Johnson comprises about 0.6% of Waypoint Wealth Partners Inc.’s portfolio, making the stock its 17th biggest position. Waypoint Wealth Partners Inc.’s holdings in Johnson & Johnson were worth $2,005,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Kovitz Investment Group Partners LLC increased its stake in Johnson & Johnson by 33.2% during the first quarter. Kovitz Investment Group Partners LLC now owns 460,924 shares of the company’s stock worth $76,440,000 after purchasing an additional 114,908 shares during the period. Cookson Peirce & Co. Inc. purchased a new stake in shares of Johnson & Johnson during the first quarter worth approximately $208,000. Vestmark Advisory Solutions Inc. increased its stake in shares of Johnson & Johnson by 143.7% during the first quarter. Vestmark Advisory Solutions Inc. now owns 81,230 shares of the company’s stock worth $13,471,000 after buying an additional 47,895 shares during the period. Lord Abbett & CO. LLC increased its stake in shares of Johnson & Johnson by 63.8% during the first quarter. Lord Abbett & CO. LLC now owns 706,099 shares of the company’s stock worth $117,099,000 after buying an additional 274,905 shares during the period. Finally, Mitsubishi UFJ Asset Management UK Ltd. increased its stake in shares of Johnson & Johnson by 200.0% during the first quarter. Mitsubishi UFJ Asset Management UK Ltd. now owns 4,500 shares of the company’s stock worth $746,000 after buying an additional 3,000 shares during the period. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $174.29 on Thursday. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The stock has a fifty day moving average price of $160.42 and a 200 day moving average price of $158.01. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $174.76. The company has a market cap of $419.75 billion, a PE ratio of 18.64, a P/E/G ratio of 2.20 and a beta of 0.41.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, topping the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%. The firm had revenue of $23.74 billion during the quarter, compared to the consensus estimate of $22.85 billion. During the same period last year, the company earned $2.82 earnings per share. The company’s revenue for the quarter was up 5.8% on a year-over-year basis. Sell-side analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be issued a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a yield of 3.0%. Johnson & Johnson’s dividend payout ratio (DPR) is 55.61%.

Analyst Ratings Changes

A number of analysts recently weighed in on JNJ shares. Leerink Partnrs lowered shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, May 13th. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Johnson & Johnson in a report on Wednesday, April 16th. Leerink Partners downgraded Johnson & Johnson from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $169.00 to $153.00 in a report on Tuesday, May 13th. Piper Sandler reaffirmed an “overweight” rating on shares of Johnson & Johnson in a report on Thursday, July 17th. Finally, UBS Group upped their price target on Johnson & Johnson from $180.00 to $190.00 and gave the company a “buy” rating in a report on Thursday, July 17th. Nine equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus target price of $174.50.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.